AR-42 (previously known as OSU-HDAC42; Arno Therapeutics) has been shown to have potent HDAC-inhibitory activity, which inhibit the GP130/STAT3 pathway to inhibit multiple myeloma cell growth62. This evidence concerns the gene STAT3 and plasma cell myeloma.